Skip to content

Effects of Sea Grape-Derived Nanoliposome Product in Adults with Prediabetes: A Randomised Controlled Clinical Trial

A randomised controlled trial to evaluate the safety, tolerability, and efficacy of a sea grape derived nanoliposome product on glycaemic control in adults with prediabetes

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12626000597392
Enrollment
200
Registered
2026-05-12
Start date
2026-07-01
Completion date
2026-09-30
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study is a Phase I randomised controlled trial evaluating a sea grape derived nanoliposome product as an adjunct to standard lifestyle care in adults with prediabetes. The trial will be conducted in primary care settings in Indonesia and will compare the intervention plus standard care with standard care alone over 90 days. The primary aim is to assess safety, tolerability, and preliminary efficacy on glycaemic control, measured by HbA1c and fasting blood glucose. Secondary outcomes include anthropometric measures, cardiometabolic risk factors, safety indicators, adherence, and acceptability. Findings from this study will inform the feasibility and design of larger trials and the potential role of this intervention in diabetes prevention strategies.

Interventions

Intervention arm: Sea grape derived nanoliposome product plus standard care (Diet, physical activity, and risk factor counselling) - Active ingredient: Caulerpa lentillifera extract - Formulation: Nanoliposome encapsulated oral capsules - Dose: 75 mg per kg body weight daily - Duration: 90 days - Mode: Oral administration - Setting: Primary care settings (Puskesmas) - Implementation strategies: The investigational product will be administered under the supervision of trained physicians at parti

Intervention arm: Sea grape derived nanoliposome product plus standard care (Diet, physical activity, and risk factor counselling) - Active ingredient: Caulerpa lentillifera extract - Formulation: Nanoliposome encapsulated oral capsules - Dose: 75 mg per kg body weight daily - Duration: 90 days - Mode: Oral administration - Setting: Primary care settings (Puskesmas) - Implementation strategies: The investigational product will be administered under the supervision of trained physicians at participating Puskesmas. The dose will be determined based on participant body weight and prescribed by the study physician in accordance with the protocol. All physicians involved in the study will receive standardised training prior to trial implementation, delivered approximately 2 to 4 weeks before commencement of participant enrolment. The training will be provided by an expert team comprising study investigators and experienced clinicians, including a diabetologist. The training will be conducted over approximately 14 to 15 hours across two days and will cover study procedures, inclusion and exclusion criteria, dosing protocols, participant safety monitoring, and study documentation requirements. The programme will include a practical component of approximately 3 to 4 hours to ensure competency in intervention delivery and study procedures. Training will be delivered in person at Universitas Airlangga Hospital, utilising its clinical trial facilities, and will be supported by structured training materials. All physicians will be provided with standard operating procedures to guide intervention delivery and ensure consistency across sites. Ongoing support and refresher guidance will be available throughout the study period as required. The trial will be conducted across three Puskesmas, each supported by a dedicated research nurse responsible for participant follow up, adherence monitoring using capsule counts and participant diaries, and coordination of study related activities.

Sponsors

Airlangga University
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
30 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

- Adults aged 30–60 years - Prediabetes defined as impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or glycated haemoglobin (HbA1c) 5.7–6.4% - Not overweight or obese (Asian cut-offs) - Clinically stable - Able to comply

Exclusion criteria

- Diagnosed diabetes - Use of glucose lowering medication (including metformin) - Major chronic disease - Pregnancy or lactation - Allergy to seaweed - Participation in other trials

Outcome results

None listed

Source: ANZCTR · Data processed: May 22, 2026